ReviewFrontiers in bioengineering and biotechnology2026
From biological scaffold to multifunctional bioplatform: research progress and applications of decellularized extracellular matrix.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decellularized extracellular matrix (dECM) is a biomaterial generated by the selective removal of cellular components from native tissues while preserving the three-dimensional ultrastructure and endogenous biochemical cues of the extracellular matrix. Owing to its favorable biocompatibility, low immunogenicity, and capacity to mimic tissue-specific microenvironments, dECM has been increasingly explored across a wide range of biomedical applications. Its role has expanded from a conventional scaffold for tissue repair to a multifunctional biomaterial platform integrating 3D bioprinting bioinks, organ-on-a-chip matrices, organoid culture systems, and immunomodulatory applications. This review summarizes recent advances in dECM preparation, engineering applications, and clinical translation between 2020 and 2026. In terms of preparation methodology, conventional single physical, chemical, or enzymatic decellularization strategies are being replaced by integrated and tissue-specific combinatorial approaches. Emerging techniques, including supercritical CO
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.